Who Paid My Doc
Ola Kawadry
Pediatric Endocrinology Oak Lawn, IL Doctor of Osteopathy
NPI 1952573552 CMS profile 43353
4440 W 95Th St, Suite 2177H, Oak Lawn, IL 60453
General payments
$770
Research payments
$0
Ownership & investment interest
$0
Through program year 2020, Ola Kawadry of Oak Lawn, IL is reported in the CMS Open Payments database as having received $770 across 14 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 51st percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2020 | General | $500 | 1 | |
| 2019 | General | $270 | 13 |
Beside peers
- Ola Kawadry
- Pediatric Endocrinology median
- Middle half of Pediatric Endocrinology
- National median
In program year 2025, general payments to Ola Kawadry were reported at $0. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.
Show as a table
| Year | Ola Kawadry | Pediatric Endocrinology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $270 | $196 | $68–$845 | $163 |
| 2020 | $500 | $124 | $37–$722 | $114 |
| 2021 | $0 | $134 | $35–$691 | $132 |
| 2022 | $0 | $177 | $47–$726 | $149 |
| 2023 | $0 | $236 | $75–$887 | $160 |
| 2024 | $0 | $259 | $91–$979 | $164 |
| 2025 | $0 | $293 | $106–$1,640 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
11
Drug cost
$612
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Lantus Insulin Glargine,hum.Rec.Anlog | Brand | 11 | $612 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.
Records
14 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Endocrinology in Illinois
Anita Swamy
Pediatric Endocrinology · Chicago, IL
Stuart Kupfer
Pediatric Endocrinology · Deerfield, IL
Mary McCauley
Pediatric Endocrinology · Winfield, IL
Kanika Ghai
Pediatric Endocrinology · Park Ridge, IL
Angela Ganan Popa
Pediatric Endocrinology · Elk Grove Village, IL
Courtney Finlayson
Pediatric Endocrinology · Chicago, IL
Related records
Pediatric Endocrinology in Illinois
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Endocrinology
Everyone recorded under this specialty, nationwide.
Doctors in Illinois
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.